CoChat

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Open access

The DOI matches its Crossref record; 102 of the 106 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of quality information regarding the prevalence and outcomes of these conditions. Collaborative registries are needed to improve health policy for the care of patients with rare dyslipidaemias.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30264-5

Cites

102 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 103 references

Cited by

See all 247

Metadata

Authors
Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., Frikke-Schmidt, R., Gaudet, D., Hovingh, G. K., Kronenberg, F., Lütjohann, D., Parhofer, K. G., Raal, F. J., Ray, K. K., Remaley, A. T., Stock, J. K., Stroes, E. S., Tokgözoğlu, L., & Catapano, A. L.
Affiliations
  • Western University (CA)
  • Sahlgrenska University Hospital (SE)
  • Columbia University (US)
  • Sapienza University of Rome (IT)
  • University of Palermo (IT)
  • Medical University of Vienna (AT)
  • University of Milan (IT)
  • Inserm (FR)
  • University of Pennsylvania (US)
  • Hôpital de Chicoutimi (CA)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Innsbruck Medical University (AT)
  • University Hospital Bonn (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • University of the Witwatersrand (ZA)
  • Imperial College London (GB)
  • National Institutes of Health (US)
  • European Atherosclerosis Society (SE)
  • Hacettepe University (TR)
Corresponding author
Hegele, Robert A
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2020-01
Volume
8
Issue
1
Pages
50-67
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2978430228
Cited by
204
References
106
Citations by year
2026: 33 · 2025: 27 · 2024: 35 · 2023: 30 · 2022: 29 · 2021: 27 · 2020: 20
FWCI
18.87
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Funders
  • Boehringer Ingelheim
  • MedImmune
  • Amgen
  • Janssen Pharmaceuticals
  • Institut de Cardiologie de Montréal
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals
  • HLS Therapeutics
  • Pfizer
  • REGENXBIO
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Unilever
  • Novo Nordisk
  • Merck
  • European Atherosclerosis Society
  • Novartis
  • European Commission
  • Sanofi
  • Daiichi-Sankyo
  • Meso Scale Diagnostics
  • Akebia Therapeutics
  • Ionis Pharmaceuticals
  • Silence Therapeutics
  • GlaxoSmithKline
  • Medicines Company
  • AstraZeneca
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
lipoprotein metabolism disorders, LDL cholesterol, triglycerides, HDL cholesterol, genotype-phenotype variability, underdiagnosis, undertreatment, gene therapy, genome sequencing, clinical management, patient registry, health policy
MeSH terms
Europe, Genotype, Humans, Phenotype, Practice Guidelines as Topic, Disease Management, Genetic Predisposition to Disease, Consensus, Rare Diseases, Dyslipidemias, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30264-5
The paper
Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., Frikke-Schmidt, R., Gaudet, D., Hovingh, G. K., Kronenberg, F., Lütjohann, D., Parhofer, K. G., Raal, F. J., Ray, K. K., Remaley, A. T., . . . Catapano, A. L. (2020). Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30264-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.